Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Marstacimab - Pfizer

Drug Profile

Marstacimab - Pfizer

Alternative Names: PF-06741086; PF-6741086

Latest Information Update: 03 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antihaemorrhagics; Coagulants; Monoclonal antibodies
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemophilia

Most Recent Events

  • 10 May 2019 Pfizer plans a phase III trial for Haemophilia (SC) in May 2019 (NCT03938792) (EudraCT2018-003660-31)
  • 03 Dec 2018 Pfizer completes a phase II trial in Haemophilia in USA, Chile, Croatia, Poland, South Africa, Switzerland, and Spain (IV) (SC) (EudraCT2016-001885-27) (NCT02974855)
  • 01 Dec 2018 Pharmacodynamics data from a preclinical study in Haemophilia presented at the 60th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top